Akebia Therapeutics Inc (AKBA)
1.82
+0.03
(+1.68%)
USD |
NASDAQ |
Nov 21, 16:00
1.81
-0.01
(-0.55%)
After-Hours: 20:00
Akebia Therapeutics Profit Margin (Quarterly): -53.54% for Sept. 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -53.54% |
| June 30, 2024 | -19.66% |
| March 31, 2024 | -55.16% |
| December 31, 2023 | 1.09% |
| September 30, 2023 | -34.46% |
| June 30, 2023 | -19.82% |
| March 31, 2023 | -67.18% |
| December 31, 2022 | -10.88% |
| September 30, 2022 | -111.0% |
| June 30, 2022 | 23.30% |
| March 31, 2022 | -101.2% |
| December 31, 2021 | -121.1% |
| September 30, 2021 | -122.1% |
| June 30, 2021 | -156.9% |
| March 31, 2021 | -133.0% |
| December 31, 2020 | -157.7% |
| Date | Value |
|---|---|
| September 30, 2020 | -99.95% |
| June 30, 2020 | -195.0% |
| March 31, 2020 | -68.66% |
| December 31, 2019 | -135.8% |
| September 30, 2019 | -59.35% |
| June 30, 2019 | -57.71% |
| March 31, 2019 | -99.66% |
| December 31, 2018 | -100.3% |
| September 30, 2018 | -48.99% |
| June 30, 2018 | -69.82% |
| March 31, 2018 | -50.99% |
| December 31, 2017 | 17.14% |
| September 30, 2017 | -56.04% |
| June 30, 2017 | -75.45% |
| March 31, 2017 | -213.5% |
| December 31, 2016 | -2.47K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-195.0%
Minimum
Jun 2020
23.30%
Maximum
Jun 2022
-81.94%
Average
-84.30%
Median
Profit Margin (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 25.86% |
| Eli Lilly and Co | 8.48% |
| Bioventus Inc | -3.47% |
| NovaBay Pharmaceuticals Inc | -49.65% |
| Palatin Technologies Inc | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Assets | -20.36% |
| Return on Invested Capital | -9.55K% |
| Gross Profit Margin (Quarterly) | 62.16% |
| Operating Margin (Quarterly) | -33.41% |
| Return on Net Operating Assets | -29.07% |